Article

ALOX5 promoter genotype and response to montelukast in moderate persistent asthma.

Institute of Biology and Molecular Genetics (IBGM/CSIC), University of Valladolid, Valladolid, Spain. <>
Respiratory Medicine (impact factor: 2.47). 07/2008; 102(6):857-61. DOI:10.1016/j.rmed.2008.01.011 pp.857-61
Source: PubMed

ABSTRACT It was hypothesized that asthmatic patients with mutant alleles in the leukotriene pathway should not respond to leukotriene receptor antagonists and the concept of a tailored treatment is increasingly supported.
Sixty-one patients (mean age 24.9 years, range 14-52) with moderate persistent asthma were clinical and immunological assess prior and after a 6-month treatment with montelukast. Tandem repeat polymorphisms were genotyped in the promoter (-147 to -176) of 5-lipoxygenase gene (ALOX5).
Thirty-two patients (52.5%) were homozygous for the five repeats allele; 17 (27.9%) were heterozygous (4/5 repeats) and 12 (19.7%) were homozygous for 4/4 repeats. After the montelukast treatment decrease number of asthma exacerbations, improvement of FEV(1) and decreased use of beta(2) agonists was observed in patients with 5/5 or 4/5 repeats. Conversely, the patients with 4/4 repeats genotype did not modify these data after treatment.
It was confirmed that ALOX5 promoter polymorphisms have a clear influence in montelukast response in atopic moderate persistent asthma patients. The genetic study could identify those patients most likely to respond to montelukast.

0 0
 · 
0 Bookmarks
 · 
28 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

5-lipoxygenase gene
 
6-month treatment
 
ALOX5
 
ALOX5 promoter polymorphisms
 
asthma exacerbations
 
asthmatic patients
 
atopic moderate persistent asthma patients
 
clear influence
 
genetic study
 
immunological
 
leukotriene receptor antagonists
 
moderate persistent asthma
 
montelukast response
 
montelukast treatment decrease number
 
mutant alleles
 
patients
 
prior
 
tailored treatment
 
Tandem repeat polymorphisms